Back to top
more

Haemonetics (HAE)

(Delayed Data from NYSE)

$76.30 USD

76.30
451,069

+1.53 (2.05%)

Updated Aug 4, 2025 04:00 PM ET

After-Market: $76.35 +0.05 (0.07%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value A Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 30% (173 out of 246)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Hologic (HOLX) to Elevate OB-GYN Training With New Partnerships

by Zacks Equity Research

Hologic's (HOLX) collaboration with AAGL and Inovus Medical is likely to optimize OB-GYN training for minimally invasive surgeries.

Indrajit Bandyopadhyay headshot

5 Medical Product Stocks to Buy Amid Industry Recovery

by Indrajit Bandyopadhyay

Despite the ongoing macro headwinds, recovering demand for medical procedures and cost-cutting initiatives should support the Zacks Medical-Products industry. SYK, BSX, ZBH, PODD and HAE are well-poised to gain from the favorable factors.

Zacks Equity Research

Here's Why Investors Should Buy Bruker (BRKR) Stock Now

by Zacks Equity Research

The strong prospects of the BSI BioSpin and CALID group are likely to bode well for Bruker (BRKR) stock.

Zacks Equity Research

Haemonetics (HAE) Moves to Strong Buy: Rationale Behind the Upgrade

by Zacks Equity Research

Haemonetics (HAE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Zacks Equity Research

Haemonetics (HAE) Announces Agreement to Acquire OpSens

by Zacks Equity Research

Haemonetics' (HAE) acquisition of OpSens will expand its leadership in the interventional cardiology market.

Zacks Equity Research

Here's Why You Should Retain Exact Sciences (EXAS) Stock Now

by Zacks Equity Research

Investors remain optimistic about Exact Sciences (EXAS) due to its strategic prioritization and positive solvency.

Zacks Equity Research

Here's Why You Should Retain Tandem Diabetes (TNDM) Now

by Zacks Equity Research

Investors remain optimistic about Tandem Diabetes (TNDM), backed by strategic developments and innovative new launches.

Zacks Equity Research

Thermo Fisher (TMO) Expands Capabilities in St. Louis Facility

by Zacks Equity Research

Thermo Fisher (TMO) expands manufacturing capacity at the St. Louis site for Biologics treatment.

Zacks Equity Research

QIAGEN (QGEN) Broadens QuantiFERON Line With EBV RUO Assay

by Zacks Equity Research

QIAGEN (QGEN) notes that T-cells are vital in combatting viral infections and the QuantiFERON-EBV RUO assay focuses on measuring the T-cell response to EBV.

Zacks Equity Research

Bruker (BRKR) Becomes Majority Investor in MIRO Analytical AG

by Zacks Equity Research

Bruker's (BRKR) majority investment in MIRO adds state-of-the-art QCL technology to the Bruker Optics gas-analysis portfolio.

Zacks Equity Research

Here's Why Investors Should Retain Integra (IART) Stock Now

by Zacks Equity Research

International expansion and the strong prospects of the CSS segment bode well for Integra (IART).

Zacks Equity Research

Penumbra (PEN) Rides on New Product Offerings as FX Woe Ails

by Zacks Equity Research

Penumbra (PEN) sees an acceleration of Lightning Bolt 7 cases as conversion from surgery, lytics and other mechanical thrombectomy products gains momentum.

Zacks Equity Research

Is Haemonetics (HAE) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Haemonetics (HAE) and Amneal Pharmaceuticals (AMRX) have performed compared to their sector so far this year.

Zacks Equity Research

Bruker (BRKR) Introduces the New Hysitron TI 990 TriboIndenter

by Zacks Equity Research

Bruker's (BRKR) TI 990 is a comprehensive advancement of its industry-leading TriboIndenter platform.

Zacks Equity Research

Here's Why You Should Retain Henry Schein (HSIC) Stock for Now

by Zacks Equity Research

Investors are optimistic about Henry Schein (HSIC), backed by the strength of the dental business and acquisitions.

Zacks Equity Research

Exact Sciences (EXAS) Aided by Innovation, Strategic Buyouts

by Zacks Equity Research

Exact Sciences (EXAS) is planning several key milestones to bring six innovative cancer diagnostics from its pipeline to patients in need.

Zacks Equity Research

Here's Why Investors Should Retain ResMed (RMD) Stock for Now

by Zacks Equity Research

Investors continue to be optimistic about ResMed (RMD) due to the core business' performance and sustained growth in the SaaS business.

Zacks Equity Research

Here's Why Haemonetics (HAE) is a Strong Growth Stock

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks Equity Research

Here's Why You Should Retain CVS Health (CVS) Stock for Now

by Zacks Equity Research

Investors continue to remain optimistic about CVS Health (CVS) due to the new acquisitions and the strong execution of the pharmacy business.

Zacks Equity Research

Zimmer Biomet (ZBH) Gains From ROSA Sales Growth Amid FX Woes

by Zacks Equity Research

Zimmer Biomet (ZBH) plans to work on the overall shift of the company's legacy knee systems to a fully rounded-out Persona portfolio.

Zacks Equity Research

Abbott (ABT) Rides on Nutrition Recovery Amid Low Testing Sales

by Zacks Equity Research

Abbott's (ABT) Nutrition business has started showing signs of recovery since the beginning of 2023.

Zacks Equity Research

Here's Why You Should Retain Hologic (HOLX) Stock for Now

by Zacks Equity Research

Investors continue to remain optimistic about Hologic (HOLX), backed by the Breast Health business' performance and international execution.

Zacks Equity Research

Here's Why Investors Should Retain Labcorp (LH) Stock for Now

by Zacks Equity Research

Investors are increasingly optimistic about Labcorp (LH) due to its progress in hospital partnerships.

Zacks Equity Research

Neogen (NEOG) Gains From Strong Segmental Sales, Innovation

by Zacks Equity Research

Within the biosecurity portfolio, Neogen (NEOG) continues to record solid growth in cleaners, disinfectants and rodenticides.

Zacks Equity Research

Here's Why Investors Should Retain STERIS (STE) Stock for Now

by Zacks Equity Research

STERIS' (STE) healthcare segment benefits from procedure recovery, boosting investors' optimism.